CCL22 and inflammatory skin disease: In particular, thymus and activation-regulated chemokines (CCL17/TARC) and macrophage-derived chemokines (CCL22/MDC), which are regulated upon inflammatory activation, are produced in keratinocytes and are considered therapeutic targets for the treatment of inflammatory skin diseases [4,5].